128 related articles for article (PubMed ID: 34437586)
21. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
[TBL] [Abstract][Full Text] [Related]
22. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A; Hellmann MD; Arniella MB; Holton M; Freeman SS; Naranbhai V; Stewart C; Leshchiner I; Kim J; Akiyama Y; Griffin AT; Vokes NI; Sakhi M; Kamesan V; Rizvi H; Ricciuti B; Forde PM; Anagnostou V; Riess JW; Gibbons DL; Pennell NA; Velcheti V; Digumarthy SR; Mino-Kenudson M; Califano A; Heymach JV; Herbst RS; Brahmer JR; Schalper KA; Velculescu VE; Henick BS; Rizvi N; Jänne PA; Awad MM; Chow A; Greenbaum BD; Luksza M; Shaw AT; Wolchok J; Hacohen N; Getz G; Gainor JF
Nat Genet; 2023 May; 55(5):807-819. PubMed ID: 37024582
[TBL] [Abstract][Full Text] [Related]
23. Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy.
Hulo P; Deshayes S; Fresquet J; Chéné AL; Blandin S; Boisgerault N; Fonteneau JF; Treps L; Denis MG; Bennouna J; Fradin D; Pons-Tostivint E; Blanquart C
Respir Res; 2024 Apr; 25(1):156. PubMed ID: 38581044
[TBL] [Abstract][Full Text] [Related]
24. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
Suresh S; Chen B; Zhu J; Golden RJ; Lu C; Evers BM; Novaresi N; Smith B; Zhan X; Schmid V; Jun S; Karacz CM; Peyton M; Zhong L; Wen Z; Sathe AA; Xing C; Behrens C; Wistuba II; Xiao G; Xie Y; Fu YX; Minna JD; Mendell JT; O'Donnell KA
Nat Cancer; 2020 May; 1(5):533-545. PubMed ID: 32984844
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 regulates inflammatory programs of macrophages from human pluripotent stem cells.
Cao H; Xiang Y; Zhang S; Chao Y; Guo J; Aurich T; Ho JW; Huang Y; Liu P; Sugimura R
Life Sci Alliance; 2024 Feb; 7(2):. PubMed ID: 37949473
[TBL] [Abstract][Full Text] [Related]
26. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract][Full Text] [Related]
27. Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
Johnson MB; Ogishi M; Domingo-Vila C; De Franco E; Wakeling MN; Imane Z; Resnick B; Williams E; Galão RP; Caswell R; Russ-Silsby J; Seeleuthner Y; Rinchai D; Fagniez I; Benson B; Dufort MJ; Speake C; Smithmyer ME; Hudson M; Dobbs R; ; Quandt Z; Hattersley AT; Zhang P; Boisson-Dupuis S; Anderson MS; Casanova JL; Tree TI; Oram RA
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38634869
[TBL] [Abstract][Full Text] [Related]
28. A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.
Altorki NK; Bhinder B; Borczuk AC; Elemento O; Mittal V; McGraw TE
Cell Rep Med; 2024 Mar; 5(3):101438. PubMed ID: 38401548
[TBL] [Abstract][Full Text] [Related]
29. PD-1: A New Candidate Target for Analgesic Peptide Design.
Zhao L; Ma Y; Song X; Wu Y; Jin P; Chen G
J Pain; 2023 Jul; 24(7):1142-1150. PubMed ID: 36781089
[TBL] [Abstract][Full Text] [Related]
30. Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.
Wangpaichitr M; Kandemir H; Li YY; Wu C; Nguyen D; Feun LG; Kuo MT; Savaraj N
Cell Dev Biol; 2017 Jun; 6(2):. PubMed ID: 28819582
[TBL] [Abstract][Full Text] [Related]
31. Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models.
Gao T; Niu L; Wu X; Dai D; Zhou Y; Liu M; Wu K; Yu Y; Guan N; Ye H
Cell Rep Med; 2024 May; 5(5):101513. PubMed ID: 38608697
[TBL] [Abstract][Full Text] [Related]
32. RNA-Seq Analysis Reveals Altered Expression of Cell Adhesion-Related Genes Following PZR Knockout in Lung Cancer Cells.
Fu Y; Li G; Fu X; Xing S; Zhao ZJ
Appl Biochem Biotechnol; 2024 Apr; 196(4):2122-2136. PubMed ID: 37470934
[TBL] [Abstract][Full Text] [Related]
33. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
[TBL] [Abstract][Full Text] [Related]
35. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
De Giglio A; Di Federico A; Nuvola G; Deiana C; Gelsomino F
Curr Oncol Rep; 2021 Aug; 23(11):126. PubMed ID: 34453261
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M; Cortellini A; Giusti R; Russo A; Zoratto F; Rastelli F; Gelibter A; Chiari R; Nigro O; De Tursi M; Bracarda S; Gori S; Grossi F; Bersanelli M; Calvetti L; Di Noia V; Scartozzi M; Di Maio M; Bossi P; Falcone A; Citarella F; Pantano F; Ficorella C; Filetti M; Adamo V; Veltri E; Pergolesi F; Occhipinti MA; Nicolardi L; Tuzi A; Di Marino P; Macrini S; Inno A; Ghidini M; Buti S; Aprile G; Lai E; Audisio M; Intagliata S; Marconcini R; Brocco D; Porzio G; Piras M; Rijavec E; Simionato F; Natoli C; Tiseo M; Vincenzi B; Tonini G; Santini D
Cancer Immunol Immunother; 2022 Apr; 71(4):865-874. PubMed ID: 34462870
[TBL] [Abstract][Full Text] [Related]
38. Current Advances and Trends in
Teo MYM; Fong JY; Lim WM; In LLA
Mol Cancer Res; 2022 Jan; 20(1):30-44. PubMed ID: 34462329
[TBL] [Abstract][Full Text] [Related]
39. Cancer evolution: Darwin and beyond.
Vendramin R; Litchfield K; Swanton C
EMBO J; 2021 Sep; 40(18):e108389. PubMed ID: 34459009
[TBL] [Abstract][Full Text] [Related]
40. The gut microbiome and efficacy of cancer immunotherapy.
Roviello G; Iannone LF; Bersanelli M; Mini E; Catalano M
Pharmacol Ther; 2022 Mar; 231():107973. PubMed ID: 34453999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
